[go: up one dir, main page]

MX2022000027A - Extracto de ca?amo para tratamiento del dolor, cancer y epilepsia en animales. - Google Patents

Extracto de ca?amo para tratamiento del dolor, cancer y epilepsia en animales.

Info

Publication number
MX2022000027A
MX2022000027A MX2022000027A MX2022000027A MX2022000027A MX 2022000027 A MX2022000027 A MX 2022000027A MX 2022000027 A MX2022000027 A MX 2022000027A MX 2022000027 A MX2022000027 A MX 2022000027A MX 2022000027 A MX2022000027 A MX 2022000027A
Authority
MX
Mexico
Prior art keywords
cancer
epilepsy
pain
animals
treatment
Prior art date
Application number
MX2022000027A
Other languages
English (en)
Inventor
Amanda Howland
Christian Kjaer
Joe Wakshlag
Original Assignee
Ellevet Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ellevet Sciences filed Critical Ellevet Sciences
Publication of MX2022000027A publication Critical patent/MX2022000027A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere a métodos para tratar la epilepsia, el cáncer y el dolor posoperatorio en sujetos veterinarios mediante el uso de composiciones farmacéuticas y formas de dosificación que comprenden extracto de cáñamo.
MX2022000027A 2019-07-02 2020-07-02 Extracto de ca?amo para tratamiento del dolor, cancer y epilepsia en animales. MX2022000027A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870043P 2019-07-02 2019-07-02
US202062962114P 2020-01-16 2020-01-16
PCT/US2020/040614 WO2021003341A1 (en) 2019-07-02 2020-07-02 Hemp extract for treatment of pain, cancer and epilepsy in animals

Publications (1)

Publication Number Publication Date
MX2022000027A true MX2022000027A (es) 2022-04-11

Family

ID=74101139

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000027A MX2022000027A (es) 2019-07-02 2020-07-02 Extracto de ca?amo para tratamiento del dolor, cancer y epilepsia en animales.

Country Status (9)

Country Link
US (1) US20230090094A1 (es)
EP (1) EP3993780A4 (es)
JP (1) JP7597780B2 (es)
CN (1) CN114727970A (es)
AU (1) AU2020298550A1 (es)
BR (1) BR112021026854A2 (es)
CA (1) CA3145830A1 (es)
MX (1) MX2022000027A (es)
WO (1) WO2021003341A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3908300A4 (en) * 2019-01-28 2022-10-19 Locus IP Company, LLC PREPARATION AND USE OF YEAST EXTRACT AS MEDICAL ADJUVANT
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
MX2022004257A (es) 2019-10-11 2022-05-26 Pike Therapeutics Inc Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales.
MX2022004258A (es) 2019-10-14 2022-05-26 Pike Therapeutics Inc Entrega transdermica de cannabidiol.
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
AU2022220037A1 (en) * 2021-02-11 2023-08-17 Portland Technology Holdings Llc Compositions and methods comprising hemp extract for the treatment of animals in need
IL311854A (en) * 2021-10-11 2024-05-01 Neurotech Int Ltd Preparations and methods for the treatment of neurological disorders with combination products
JP2024536075A (ja) * 2021-10-11 2024-10-04 ニューロテック インターナショナル リミテッド 神経障害を処置するための組成物および方法
CA3233060A1 (en) * 2021-10-13 2023-04-20 Portland Technology Holdings Llc Hemp extract for treatment of pain, cancer and epilepsy in animals
US20230131424A1 (en) * 2021-10-21 2023-04-27 Elise Nicks Covenant Pain Relieving Cream
US12440454B2 (en) * 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2024073812A1 (en) * 2022-10-06 2024-04-11 Neurotech International Ltd Methods for treating paediatric neurological disorders
EP4598517A1 (en) * 2022-10-07 2025-08-13 Canaquest Medical Corp. Composition for treating epilepsy
EP4608426A1 (en) 2022-10-26 2025-09-03 Ecofibre USA Inc. Stabilized compositions comprising cannabidiol
WO2024097631A2 (en) * 2022-11-02 2024-05-10 Morehouse School Of Medicine Methods of treating pain and drepression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2760452A4 (en) * 2011-09-30 2015-04-01 Glaxosmithkline Llc METHODS OF TREATING CANCER
US9254272B2 (en) * 2011-11-30 2016-02-09 Sutter West Bay Hospitals Resorcinol derivatives
CA2931486A1 (en) * 2013-11-05 2015-05-14 Ardent Llc Sublingual cannabis dosage form and methods of making and using the same
EA201791299A1 (ru) * 2014-12-12 2017-12-29 ОХАЙ ЭНЕРДЖЕТИКС ПиБиСи Микроинкапсулированные композиции каннабиноидов
AU2016215094B2 (en) * 2015-02-05 2019-09-26 Colorado Can Llc Purified CBD and CBDA, and methods, compositions and products employing CBD or CBDA
BR112018008601A2 (pt) * 2015-10-27 2018-10-30 Jay Pharma Inc composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
WO2017151980A1 (en) * 2016-03-03 2017-09-08 Segreti Louis M Cannabis-based bioactive formulations and methods for use thereof
US10265362B2 (en) * 2016-04-12 2019-04-23 Scott Schaneville Ingestible films having substances from hemp or cannabis
CA3020616A1 (en) * 2016-04-12 2017-10-19 Habi Pharma Pty Ltd Liposomal preparation and methods of treatment
LT6486B (lt) 2016-04-13 2018-01-10 UAB "SatiMed" Aliejinio gelio kompozicija su aktyviausiais junginiais iš c. sativa ir m. arvensis ir jos pateikimo sistema, skirta giliųjų audinių uždegimo ir skausmo mažinimui
AU2018239222A1 (en) * 2017-03-18 2019-09-26 Thomas A. Asquith Pet food including cannabidiolic acid
CA3076963C (en) * 2017-11-30 2022-03-29 Canopy Growth Corporation Liquid dosage forms comprising cannabis, methods of making and use
MX2020010603A (es) * 2018-04-09 2021-02-02 Ellevet Sciences Extracto de cáñamo para tratamiento de dolor en animales.

Also Published As

Publication number Publication date
EP3993780A4 (en) 2023-07-26
AU2020298550A1 (en) 2022-02-17
US20230090094A1 (en) 2023-03-23
WO2021003341A1 (en) 2021-01-07
CN114727970A (zh) 2022-07-08
JP2022539590A (ja) 2022-09-12
JP7597780B2 (ja) 2024-12-10
CA3145830A1 (en) 2021-01-07
EP3993780A1 (en) 2022-05-11
BR112021026854A2 (pt) 2022-03-29

Similar Documents

Publication Publication Date Title
MX2022000027A (es) Extracto de ca?amo para tratamiento del dolor, cancer y epilepsia en animales.
MX2020010603A (es) Extracto de cáñamo para tratamiento de dolor en animales.
MX385543B (es) Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b.
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
CL2018000818A1 (es) Composición de oligonucleotidos; métodos para alterar el empalme de un transcripto blanco; y uso de la composición para tratar distrofia muscular de duchenne.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX394961B (es) Composiciones para usarse en el tratamiento de enfermedades relacionadas con la interleucina 6
MX2022010774A (es) Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
PE20191149A1 (es) Uso farmaceutico de una composicion que contiene pirfenidona de liberacion prolongada (pfd-lp) para la reversion y tratamiento de la esteatohepatitis humana (nafld/nash)
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2024004319A (es) Extracto de ca?amo para el tratamiento de dolor, cancer y epilepsia en animales.
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
CL2021000531A1 (es) Métodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
MX2020010747A (es) Formulaciones topicas que comprenden estroncio y metilsulfonilmetano (msm) y metodos de tratamiento.
CL2011000387A1 (es) Combinacion que comprende a) 6-dimetilaminometil-1-(3-metoxifenil)-ciclohexano-1,3-diol y b) paracetamol; forma de dosificacion; uso para tratar osteoartritis y dolor.
MX2021008303A (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa.
CO2018004803A2 (es) Compuestos oxa-diazaspiro que tienen actividad contra el dolor
CL2022003426A1 (es) Composición farmacéutica acuosa de levilimab y su uso
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
EA202190294A1 (ru) Комбинированная терапия для лечения рака